Skip to main content
SpringerLink
Log in

Metastatic Tumors

  • Chapter
Surgical Pathology of Liver Tumors

  • 1935 Accesses

Abstract

Metastasis to the liver is common from tumors arising in various organs. Distinguishing metastatic tumors from primary hepatic tumors is important for prognosis and therapy. This chapter enumerates and discusses malignant neoplasms that commonly metastasize to the liver and examines their differential diagnoses, focusing on the histologic and immunohistochemical features that help distinguish metastases from primary hepatic tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Disibio G, French SW. Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med. 2008;132:931–9.

    PubMed  Google Scholar 

  2. Geller SA, Dhall D, Alsabeh R. Application of immunohistochemistry to liver and gastrointestinal neoplasms: liver, stomach, colon, and pancreas. Arch Pathol Lab Med. 2008;132:490–9.

    PubMed  Google Scholar 

  3. Pan CC, Chen PC, Tsay SH, Ho DM. Differential immunoprofiles of hepatocellular carcinoma, renal cell carcinoma, and adrenocortical carcinoma: a systemic immunohistochemical survey using tissue array technique. Appl Immunohistochem Mol Morphol. 2005;13:347–52.

    Article  CAS  PubMed  Google Scholar 

  4. Sangoi AR, Fujiwara M, West RB, Montgomery KD, Bonventre JV, Higgins JP, et al. Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases. Am J Surg Pathol. 2011;35:678–86.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Tong GX, Yu WM, Beaubier NT, Weeden EM, Hamele-Bena D, Mansukhani MM, et al. Expression of PAX8 in normal and neoplastic renal tissues: an immunohistochemical study. Mod Pathol. 2009;22:1218–27.

    Article  CAS  PubMed  Google Scholar 

  6. Mentrikoski MJ, Wendroth SM, Wick MR. Immunohistochemical distinction of renal cell carcinoma from other carcinomas with clear-cell histomorphology: utility of CD10 and CA-125 in addition to PAX-2, PAX-8, RCCma, and adipophilin. Appl Immunohistochem Mol Morphol. 2014;22:635–41.

    Article  CAS  PubMed  Google Scholar 

  7. Murakata LA, Ishak KG, Nzeako UC. Clear cell carcinoma of the liver: a comparative immunohistochemical study with renal clear cell carcinoma. Mod Pathol. 2000;13:874–81.

    Article  CAS  PubMed  Google Scholar 

  8. Kakar S, Muir T, Murphy LM, Lloyd RV, Burgart LJ. Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma. Am J Clin Pathol. 2003;119:361–6.

    Article  PubMed  Google Scholar 

  9. Yan BC, Gong C, Song J, Krausz T, Tretiakova M, Hyjek E, et al. Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol. 2010;34:1147–54.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Renshaw AA, Granter SR. A comparison of A103 and inhibin reactivity in adrenal cortical tumors: distinction from hepatocellular carcinoma and renal tumors. Mod Pathol. 1998;11:1160–4.

    CAS  PubMed  Google Scholar 

  11. Ghorab Z, Jorda M, Ganjei P, Nadji M. Melan A (A103) is expressed in adrenocortical neoplasms but not in renal cell and hepatocellular carcinomas. Appl Immunohistochem Mol Morphol. 2003;11:330–3.

    Article  CAS  PubMed  Google Scholar 

  12. Wang JH, Dhillon AP, Sankey EA, Wightman AK, Lewin JF, Scheuer PJ. ‘Neuroendocrine’ differentiation in primary neoplasms of the liver. J Pathol. 1991;163:61–7.

    Article  CAS  PubMed  Google Scholar 

  13. Atwell TD, Lloyd RV, Nagorney DM, Fidler JL, Andrews JC, Reading CC. Peritumoral steatosis associated with insulinomas: appearance at imaging. Abdom Imaging. 2008;33:571–4.

    Article  PubMed  Google Scholar 

  14. Nakatsura T, Kageshita T, Ito S, Wakamatsu K, Monji M, Ikuta Y, et al. Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res. 2004;10:6612–21.

    Article  CAS  PubMed  Google Scholar 

  15. Jinawath A, Akiyama Y, Yuasa Y, Pairojkul C. Expression of phosphorylated ERK1/2 and homeodomain protein CDX2 in cholangiocarcinoma. J Cancer Res Clin Oncol. 2006;132:805–10.

    Article  CAS  PubMed  Google Scholar 

  16. Chu PG, Schwarz RE, Lau SK, Yen Y, Weiss LM. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol. 2005;29:359–67.

    Article  PubMed  Google Scholar 

  17. Hinoi T, Tani M, Lucas PC, Caca K, Dunn RL, Macri E, et al. Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol. 2001;159:2239–48.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. McGregor DK, Wu TT, Rashid A, Luthra R, Hamilton SR. Reduced expression of cytokeratin 20 in colorectal carcinomas with high levels of microsatellite instability. Am J Surg Pathol. 2004;28:712–8.

    Article  PubMed  Google Scholar 

  19. Gurzu S, Jung I. Aberrant pattern of the cytokeratin 7/cytokeratin 20 immunophenotype in colorectal adenocarcinomas with BRAF mutations. Pathol Res Pract. 2012;208:163–6.

    Article  CAS  PubMed  Google Scholar 

  20. Liu D, Momoi H, Li L, Ishikawa Y, Fukumoto M. Microsatellite instability in thorotrast-induced human intrahepatic cholangiocarcinoma. Int J Cancer. 2002;102:366–71.

    Article  CAS  PubMed  Google Scholar 

  21. Limpaiboon T, Krissadarak K, Sripa B, Jearanaikoon P, Bhuhisawasdi V, Chau-in S, et al. Microsatellite alterations in liver fluke related cholangiocarcinoma are associated with poor prognosis. Cancer Lett. 2002;181:215–22.

    Article  CAS  PubMed  Google Scholar 

  22. Liengswangwong U, Karalak A, Morishita Y, Noguchi M, Khuhaprema T, Srivatanakul P, et al. Immunohistochemical expression of mismatch repair genes: a screening tool for predicting mutator phenotype in liver fluke infection-associated intrahepatic cholangiocarcinoma. World J Gastroenterol. 2006;12:3740–5.

    PubMed Central  CAS  PubMed  Google Scholar 

  23. Karagkounis G, Torbenson MS, Daniel HD, Azad NS, Diaz Jr LA, Donehower RC, et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer. 2013;119:4137–44.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Nielsen K, Rolff HC, Eefsen RL, Vainer B. The morphological growth patterns of colorectal liver metastases are prognostic for overall survival. Mod Pathol. 2014;27:1641–8.

    Article  CAS  PubMed  Google Scholar 

  25. Morris-Stiff G, White AD, Gomez D, Cameron IC, Farid S, Toogood GJ, et al. Nodular regenerative hyperplasia (NRH) complicating oxaliplatin chemotherapy in patients undergoing resection of colorectal liver metastases. Eur J Surg Oncol. 2014;40:1016–20.

    Article  CAS  PubMed  Google Scholar 

  26. Pawlik TM, Olino K, Gleisner AL, Torbenson M, Schulick R, Choti MA. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg. 2007;11:860–8.

    Article  PubMed  Google Scholar 

  27. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065–72.

    Article  CAS  PubMed  Google Scholar 

  28. Surrey LF, Frank R, Zhang PJ, Furth EE. TTF-1 and Napsin-A are expressed in a subset of cholangiocarcinomas arising from the gallbladder and hepatic ducts: continued caveats for utilization of immunohistochemistry panels. Am J Surg Pathol. 2014;38:224–7.

    Article  PubMed  Google Scholar 

  29. Fan ZJ, Wu Y, Wang ZJ. Expression of estrogen receptor and progesterone receptor in hilar cholangiocarcinoma and their clinical significances. Zhonghua Yi Xue Za Zhi. 2005;85:2651–3.

    CAS  PubMed  Google Scholar 

  30. Yang Z. The utility of villin and mammaglobin in the differential diagnosis between intrahepatic cholangiocarcinoma and breast cancer. Appl Immunohistochem Mol Morphol. 2015;23(1):19–25.

    Article  CAS  PubMed  Google Scholar 

  31. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol. 2004;45:586–92. discussion 92.

    Article  CAS  PubMed  Google Scholar 

  32. Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology. 2000;36:415–20.

    Article  CAS  PubMed  Google Scholar 

  33. Ordonez NG. Value of thyroid transcription factor-1 immunostaining in distinguishing small cell lung carcinomas from other small cell carcinomas. Am J Surg Pathol. 2000;24:1217–23.

    Article  CAS  PubMed  Google Scholar 

  34. Stavrou GA, Flemming P, Oldhafer KJ. Liver resection for metastasis due to malignant mesenchymal tumours. HPB (Oxford). 2006;8:110–3.

    Article  Google Scholar 

  35. Bosman FCF, Hruban RH, Theise ND. WHO classification of tumors of the digestive system. Lyon: IARC; 2010.

    Google Scholar 

  36. Frankel TL, D’Angelica MI. Hepatic resection for colorectal metastases. J Surg Oncol. 2014;109:2–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN, 55905, USA

    Vishal S. Chandan M.D.

Authors
  1. Vishal S. Chandan M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vishal S. Chandan M.D. .

Editor information

Editors and Affiliations

  1. Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA

    Taofic Mounajjed

  2. Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA

    Vishal S. Chandan

  3. Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA

    Michael S. Torbenson

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Chandan, V.S. (2015). Metastatic Tumors. In: Mounajjed, T., Chandan, V., Torbenson, M. (eds) Surgical Pathology of Liver Tumors. Springer, Cham. https://doi.org/10.1007/978-3-319-16089-4_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-16089-4_15

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-16088-7

  • Online ISBN: 978-3-319-16089-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation